Amarillo Biosciences Inc  

(Public, OTCMKTS:AMARQ)   Watch this stock  
Find more results for OTC:AMAR
Dec 16 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.06
Open     -
Vol / Avg. 0.00/198,019.00
Mkt cap 2.57M
P/E     -
Div/yield     -
EPS -0.01
Shares 73.29M
Beta -0.60
Inst. own 0%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -313.61% -450.23%
Return on average equity - -
Employees 3 -
CDP Score - -


4134 Business Park Drive
United States - Map
+1-806-3761741 (Phone)

Website links


Amarillo Biosciences, Inc. (ABI) is a specialty biopharmaceutical company. The Company is engaged in developing biologics for the treatment of human and animal diseases. As of December 31, 2013, its focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a low dose oral form. As of December 31, 2013, the Company owned or licensed five issued patents related to the low-dose oral delivery of interferon and one issued patent on its dietary supplement, Maxisal. The Company has completed more than 100 pre-clinical (animal) and human studies on the safety and efficacy of low-dose orally administered interferon. The Company also has a dietary supplement product, Maxisal that is useful in the symptomatic relief of dry mouth.

Officers and directors

Stephen T. Chen Ph.D. Chairman of the Board, Chief Executive Officer
Age: 63
Bernard Cohen Chief Financial Officer, Vice President, IR Contact Officer
Age: 59
Yasushi Chikagami Director
Age: 73
Marian Tibbits Director
Age: 55
Paul Tibbits Director
Age: 72